GenoLogics Announces Bioinformatics Partnership with Illumina
BEYOND GENOME CONFERENCE, San Francisco, CA, June 21, 2007 -GenoLogics, a leading developer of lab and data management software solutions for life sciences research, today announced that it has penned an agreement with Illumina, Inc. to become a technology partner and participant in IlluminaConnect, a bioinformatics software program established by Illumina to advance data integration and analysis among the life science community.
GenoLogics will build integrations into Geneus that support Illumina?s BeadArray technology platforms and software for both gene expression and genotyping applications. Geneus includes science-specific modules that are purposed for multiple genomics application areas, and is built on an enterprise laboratory information management system (LIMS) platform designed for scientific lab and data management.
Omoshile Clement, Ph.D., Senior Product Manager, Platforms at Illumina commented, "We are very happy to welcome GenoLogics as a new IlluminaConnect partner, and we look forward to working with them to develop integrations to our technology platforms for genotyping and gene expression applications."
?I am very excited about our partnership with Illumina. We are looking forward to offering Geneus with integrations to their BeadArray analysis software, BeadStudio, which will enable our customers with gene expression and genotyping applications to tie their data together using one integrating LIMS system. We will work closely with Illumina to ensure we develop seamless integrations that provide end-to-end solutions for researchers using Illumina genomics software and technologies,? said Jason Wilson, Product Manager at GenoLogics.
The most significant benefit from this partnership for customers ?this integration to Illumina software will enable customers to interconnect the Illumina technologies i n their lab with a LIMS and data management system developed specifically to address gene expression and genotyping workflows and genomics applications. This will allow for smooth data flow from one system to another with an integrating LIMS system that acts as the informatics backbone in one or multiple labs.
GenoLogics CEO, Michael Ball adds, "Our partnership with Illumina extends our network of strategic partners, building on one of our core differentiators. Our strong ties with best-in-class vendors enable us to provide end-to-end solutions for applications such as translational medicine and systems biology."
GenoLogics' Geneus provides LIMS functionality specifically for gene expression and genotyping applications and integrates to a wide variety of genomics instruments and software from best-in-class vendors, such as Illumina.
GenoLogics is the leading provider of bioinformatics software solutions that help life science laboratories specializing in the field of proteomics, genomics, and systems biology research to manage, integrate, and analyze enormous volumes of scientific and lab data. The Company's mission is to catalyze life sciences research with a collaborative data management software platform, advancing the early detection, prevention, and treatment of disease. For more information, please visit www.genologics.com.
Illumina, Inc. (NASDAQ: ILMN) is a leading developer, manufacturer, and marketer of next-generation life science tools and integrated systems for the large-scale analysis of genetic variation and biological function. Using our proprietary technologies, we provide a comprehensive line of products and services that currently serve the sequencing, genotyping, and gene expression markets, and we expect to enter the market for molecular diagnostics. Our customers include leading genomic research centers, pharmaceutic al companies, academic institutions, clinical research organizations, and biotechnology companies. Our tools provide researchers around the world with the performance, throughput, cost effectiveness, and flexibility necessary to perform the billions of genetic tests needed to extract valuable medical information from advances in genomics and proteomics. We believe this information will enable researchers to correlate genetic variation and biological function, which will enhance drug discovery and clinical research, allow diseases to be detected earlier, and permit better choices of drugs for individual patients. For more information, please visit www.Illumina.com.
GenoLogics Life Sciences Software, Inc. Tanis MacSween Manager, Marketing Communications 250.483.7063 email@example.com
Maurissa Bornstein, Public Relations Manager Illumina, Inc. Ph: 858.332.5055 Email: firstname.lastname@example.org